Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

<jats:p>Asthma and chronic obstructive pulmonary disease (COPD) are two prevalent chronic airway diseases that have a high personal and social impact. They likely represent a continuum of different diseases that may share biological mechanisms (<jats:italic>i.e.</jats:italic> endotypes), and present similar clinical, functional, imaging and/or biological features that can be observed (<jats:italic>i.e.</jats:italic> phenotypes) which require individualised treatment. Precision medicine is defined as “treatments targeted to the needs of individual patients on the basis of genetic, biomarker, phenotypic, or psychosocial characteristics that distinguish a given patient from other patients with similar clinical presentations”. In this Perspective, we propose a precision medicine strategy for chronic airway diseases in general, and asthma and COPD in particular.</jats:p>

Original publication

DOI

10.1183/13993003.01359-2015

Type

Journal article

Journal

European Respiratory Journal

Publisher

European Respiratory Society (ERS)

Publication Date

02/2016

Volume

47

Pages

410 - 419